Phreesia, Inc. $PHR Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group reduced its holdings in Phreesia, Inc. (NYSE:PHR) by 9.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 798,945 shares of the company’s stock after selling 82,071 shares during the period. Schroder Investment Management Group’s holdings in Phreesia were worth $18,815,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Royal Bank of Canada grew its stake in Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after acquiring an additional 16,309 shares during the period. AQR Capital Management LLC increased its stake in shares of Phreesia by 471.2% during the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after purchasing an additional 132,015 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after purchasing an additional 2,158 shares during the last quarter. NewEdge Advisors LLC lifted its stake in Phreesia by 262.7% in the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after buying an additional 11,181 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Phreesia by 0.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after buying an additional 2,402 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on PHR shares. Canaccord Genuity Group decreased their target price on Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, December 9th. DA Davidson lowered their target price on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. BMO Capital Markets began coverage on shares of Phreesia in a research report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 target price for the company. Barclays decreased their price target on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 16th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $35.00 price objective on shares of Phreesia in a report on Monday, December 8th. Seventeen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.12.

Insider Activity

In related news, insider Evan Roberts sold 6,317 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $107,452.17. Following the completion of the transaction, the insider directly owned 834,632 shares in the company, valued at $14,197,090.32. This trade represents a 0.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Balaji Gandhi sold 8,009 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09. Following the sale, the chief financial officer owned 156,231 shares in the company, valued at $2,657,489.31. This trade represents a 4.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 60,766 shares of company stock worth $1,013,817 in the last quarter. Insiders own 5.50% of the company’s stock.

Phreesia Stock Performance

NYSE:PHR opened at $11.01 on Friday. Phreesia, Inc. has a fifty-two week low of $10.99 and a fifty-two week high of $32.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The company has a 50 day moving average price of $13.81 and a 200 day moving average price of $19.37. The stock has a market capitalization of $663.97 million, a P/E ratio of -110.12 and a beta of 0.67.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. During the same quarter in the previous year, the company earned ($0.25) earnings per share. The firm’s quarterly revenue was up 12.7% compared to the same quarter last year. Equities research analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current year.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.